William Chase on Abbott's M&A strategy - The Deal Pipeline (SAMPLE CONTENT: NEED AN ID?)
Subscriber Content Preview | Request a free trialSearch  
  Go

Video

Share  |  Reprint

William Chase on Abbott's M&A strategy

Published November 19, 2012 at 1:04 PM


William Chase, Abbott Laboratories' vice president of licensing and acquisitions, and The Deal Pipeline's Ben Fidler discuss the pharmaceutical giant's acquisition strategy as it prepares to split into two different companies at the start of 2013. - George White

Share:

Meet the journalists



Movers & Shakers

Launch Movers and shakers slideshow

Thomas Montag was named sole chief operating officer at Bank of America Merrill Lynch. For other updates launch today's Movers & shakers slideshow.

Video

Andy Levine of Jones Day discusses the future of Chinese M&A

Andy Levine, an M&A partner at Jones Day in New York, believes that increased buying activity by Chinese companies will be a key driver of global M&A over the next decade. The Chinese have been big buyers of natural resources in Australia, Africa and South America, and Shuanghui International Holdings' purchase of Smithfield Foods last year was a sign of China's increased interest in U.S. companies. The deal stirred some protectionist rumblings in the U.S., but CFIUS approved the transaction, and Levine believes that decision is a positive sign for the future of Chinese M&A activity in the U.S. More video

Sectors